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Abstract: Acute pulmonary hypertension leading to right ventricular failure and circulatory collapse is usually caused by thromboembolic
obstruction of the pulmonary circulation. However, in rare instances, other causes can be associated with a similar clinical presentation. We
present and discuss the clinical histories of two patients with acute right ventricular failure due to an atypical cause of pulmonary hyperten-
sion, disseminated pulmonary tumor embolism.
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The acute onset of pulmonary hypertension (PH) associated with
right ventricular (RV) failure is generally caused by deep venous
thrombosis followed by proximal embolization of the pulmonary
circulation. Much less commonly, other pathological processes can
result in pulmonary vascular occlusion and acute PH, as illustrated
by the report of two patients with massive obstruction of the distal
pulmonary vasculature by circulating tumor cells followed by acute
RV failure and death.
CASE REPORTS
Patient 1 was a 67-year-old man with a history of nonmetastatic
bladder cancer treated by cystectomy 9 months before presentation
and a recent uncomplicated incisional hernia repair. He presented
to a community hospital with dyspnea and general weakness. Physi-
cal examination, chest radiograph, and electrocardiogram ﬁndings
and laboratory test results were unremarkable except for a urine
culture positive for Escherichia coli. Treatment with oral ciproﬂoxa-
cin was started. After 3 days, the patient’s condition deteriorated,
with worsening dyspnea and hypotension. Computed tomography
(CT) of the chest was described as unremarkable and, in particular,
ruled out pulmonary embolism or pneumonia. The patient was
admitted to the intensive care unit (ICU) for possible urosepsis and
was treated with piperacillin-tazobactam and norepinephrine. Be-
cause of further deterioration of his condition, he was transferred
to our institution. On arrival, severe hypoxemia, lactic acidosis (lac-
tate level, 15 mmol/L), and muscular exhaustion were noted, and
urgent endotracheal intubation was required. The procedure was
complicated by severe hypotension and pulseless electrical activity
cardiac arrest. A transesophageal electrocardiogram (ECG) obtained
during cardiopulmonary resuscitation (CPR) revealed massive RV
dilatation. CPR was stopped after 45 minutes due to refractory car-
diac arrest. Clinical diagnosis was cardiogenic shock due to acute
RV failure of unknown etiology. Postmortem examination revealed
innumerable carcinomatous microemboli massively showering pul-
monary capillaries, which explained the resulting PH. As a conse-
quence, myointimal hyperplasia and thrombosis of medium-sized
arteries were observed, as was capillary congestion (Fig. 1A–1D).
Tumor microemboli were also found in massively dilated hepatic
sinusoids, the heart, the spleen, and the pancreas. Despite extensive
sampling, tumor cells were found only within vessels, without any
parenchymal inﬁltration. Tumor cells had stain ﬁndings positive for
cytokeratin 7 and 20, compatible with an urothelial origin.
Patient 2 was a 52-year-old woman with no relevant medical
history. She presented with a 3-month history of weakness and dif-
fuse back pain and was admitted for worsening dyspnea. Physical
examination revealed a mass in the left breast. ECG and chest ra-
diograph ﬁndings were unremarkable. Thoracoabdominal CT was
negative for pulmonary emboli but revealed bilateral pulmonary in-
terstitial inﬁltrates, liver nodules, and osteolytic vertebral lesions. Be-
cause of severe hypoxemia and hemodynamic instability, the patient
was admitted to the ICU. Echocardiography revealed massive RV
dilatation, and a pulmonary artery catheter demonstrated severe PH
(mean pulmonary artery pressure, 57 mmHg) with low cardiac out-
put (3 L/min). The patient was treated with inhaled nitric oxide,
intravenous milrinone, and norepinephrine for rapidly worsening
RV failure and refractory cardiogenic shock, which led to death after
3 days. Our clinical diagnosis was metastatic breast cancer with PH
and acute RV failure of unknown etiology. Autopsy revealed a pri-
mary ductal breast carcinoma with widespread metastases. Similar
to our ﬁrst case, microscopic evaluation of the lungs showed massive
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obstruction of the distal pulmonary vasculature by multiple tumor
microemboli, which provided the rationale for the acute RV failure
(Fig. 1E, 1F ).
DISCUSSION
Disseminated microvascular pulmonary tumor embolism usually
has a fulminant course,1 as illustrated by our two clinical cases. In
this condition, pulmonary capillaries are obstructed by tumor cells.
Secondary thrombosis of larger arteries as well as myointimal hy-
perplasia contribute to the resulting PH.2 These irreversible changes
lead to increased pulmonary vascular resistance and right heart fail-
ure. For the two patients whose cases are presented herein, most
emboli seen on postmortem examination consisted of tumor cells,
either isolated or in small clusters of 1–3 cells blocked in numerous
alveolar capillaries. The overall tumoral circulating mass was thus
important and involved all ﬁve lobes homogenously. Secondary ar-
teriolar remodeling was present but played a limited role in vascular
volume occlusion.
It is worth mentioning that many other mechanisms may pro-
mote the development of PH in patients with cancer, although none
of these causes could be traced in our patients. First, cancer is a well
recognized risk factor for chronic thromboembolic pulmonary hy-
pertension.3 Second, chemotherapy may induce PH, as illustrated by
reports of severe precapillary PH induced by the tyrosine kinase in-
hibitor dasatinib4 and of veno-occlusive diseases associated with vari-
ous chemotherapy, including mitomycin, bleomycin, and carmustin as
well as gemcitabine.5 In addition, various chemotherapeutic agents, as
well as radiation therapy, may elicit cardiotoxicity, resulting in left-
heart dysfunction and postcapillary PH.6 Also, pulmonary toxicity
associated with various anticancer therapies can lead to altered lung
function7 and subsequent hypoxia-associated PH. Finally, mechanical
compression of pulmonary vessels by metastatic hilar lymph node,
which may increase pulmonary arterial pressure, has also been re-
ported.8
Disseminated pulmonary tumor embolism is a common autopsy
ﬁnding in patients with cancer, but it is rarely diagnosed premor-
tem.2 It should be suspected in a patient with cancer who has dys-
pnea, hypoxemia, and unexplained PH.9 Our two cases should be a
reminder for the reader that such disease might occur in any patient
with controlled or uncontrolled neoplasia. Contrast-enhanced CT
and pulmonary angiography are not helpful to detect microemboli,
and their negative predictive value is low. Ventilation and perfu-
sion scans might be of interest; however, they are typically difﬁcult
to perform for patients whose conditions are unstable.10,11 Aspira-
tion cytology of pulmonary arterial blood is invasive but may con-
ﬁrm the diagnosis in some cases.12
Treatment possibilities for diffuse pulmonary vascular metasta-
sis are extremely limited. Early initiation of targeted chemotherapy
is the only therapeutic option. Although its efﬁciency remains very
low,13 favorable outcomes can be seen in highly chemosensitive tu-
mors, such as choriocarcinoma or nephroblastoma.14 In those cases,
temporary cardiopulmonary support with extracorporeal membrane
oxygenation may be discussed.
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